These three immune checkpoints have been the focus of research in BCa treatment, and previous studies have found that PD‐L1 can bind to PD‐1 on T cells, B cells, and macrophages activated on the surface of tumor cells, thus showing immunosuppressive effects.46, 47, 48. The gene discussed is CD274; the disease is neoplasm.